Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer
- 1 January 2001
- Vol. 57 (1), 108-111
- https://doi.org/10.1016/s0090-4295(00)00896-7
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancerThe Annals of Thoracic Surgery, 1999
- F-18 FDG Whole-Body Positron Emission Tomography Scan in Primary Breast SarcomaClinical Nuclear Medicine, 1998
- Effectiveness of Positron Emission Tomography for the Detection of Melanoma MetastasesAnnals of Surgery, 1998
- Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomasThe Journal of Bone and Joint Surgery, 1998
- POSITRON EMISSION TOMOGRAPHY IN UROLOGICAL ONCOLOGYJournal of Urology, 1998
- Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomographyAnnals of Surgical Oncology, 1997
- PET in oncology: Will it replace the other modalities?Seminars in Nuclear Medicine, 1997
- Metabolic Imaging of Untreated Prostate Cancer by Positron Emission Tomography with sup 18 Fluorine-Labeled DeoxyglucoseJournal of Urology, 1996
- Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studiesAmerican Journal of Roentgenology, 1988